PFS
CPRX icon

Prospera Financial Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Prospera Financial Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,128
Closed -$188K – 1131
2024
Q2 		$188K Sell
12,128
-3,945
-25% -$61.4K 0.01% 1077
2024
Q1 		$256K Sell
16,073
-2,419
-13% -$36.5K 0.01% 957
2023
Q4 		$311K Buy
18,492
+1,351
+8% +$18.5K 0.01% 833
2023
Q3 		$200K Hold
17,141
– – 0.01% 950
2023
Q2 		$230K Sell
17,141
-311
-2% -$4.47K 0.01% 905
2023
Q1 		$289K Buy
17,452
+631
+4% +$10.4K 0.01% 797
2022
Q4 		$313K Sell
16,821
-9,791
-37% -$151K 0.02% 684
2022
Q3 		$341K Sell
26,612
-1,932
-7% -$22.9K 0.02% 618
2022
Q2 		$200K Sell
28,544
-2,260
-7% -$16.6K 0.01% 737
2022
Q1 		$255K Sell
30,804
-4,586
-13% -$32.4K 0.01% 793
2021
Q4 		$240K Buy
+35,390
New +$233K 0.01% 775

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Prospera Financial Services's CPRX Position: Q3 2024 in Review

Prospera Financial Services sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 12,128 shares — an estimated $188K sold.

Prospera Financial Services first reported a position in CPRX in Q4 2021 and held it in 11 quarters. The position peaked at $341K in Q3 2022. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • Prospera Financial Services reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Prospera Financial Services sold 12,128 Catalyst Pharmaceutical shares in Q3 2024, an estimated $188K.
  • Prospera Financial Services first reported a position in Catalyst Pharmaceutical in Q4 2021 and held it in 11 quarters.
  • Prospera Financial Services's Catalyst Pharmaceutical position peaked at $341K in Q3 2022.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Prospera Financial Services's 13F filing for Q3 2024, filed 7 Nov 2024.